Advanced

Inhibitor development: patient-determined risk factors.

Astermark, Jan LU (2010) In Haemophilia 16. p.66-70
Abstract
Summary. The reasons that inhibitory factor VIII antibodies develop in only a fraction of patients with haemophilia A remain unclear, but studies of genetically related subjects have indicated that the immunological outcome of replacement therapy is to a large extent determined by patient-related risk factors. Non-genetic factors will also influence the inhibitor risk, since events challenging the immune system will elicit and stimulate immune regulatory processes with the potential of modifying the immune response. Further insight into the immunological pathways and risk factors involved will be important in order to better predict and prevent this complication. This review will briefly summarize the data obtained to date in unrelated and... (More)
Summary. The reasons that inhibitory factor VIII antibodies develop in only a fraction of patients with haemophilia A remain unclear, but studies of genetically related subjects have indicated that the immunological outcome of replacement therapy is to a large extent determined by patient-related risk factors. Non-genetic factors will also influence the inhibitor risk, since events challenging the immune system will elicit and stimulate immune regulatory processes with the potential of modifying the immune response. Further insight into the immunological pathways and risk factors involved will be important in order to better predict and prevent this complication. This review will briefly summarize the data obtained to date in unrelated and related subjects in the Malmö International Brother Study (MIBS) regarding genetic factors and discuss how these factors might interact with non-genetically determined factors and events. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Haemophilia
volume
16
pages
66 - 70
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • wos:000278325600012
  • pmid:19298384
  • scopus:77953218097
ISSN
1351-8216
DOI
10.1111/j.1365-2516.2008.01923.x
language
English
LU publication?
yes
id
a7554dc4-cbed-4e2e-ba74-601b60e88319 (old id 1367656)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19298384?dopt=Abstract
date added to LUP
2009-04-08 16:18:37
date last changed
2018-07-15 04:18:45
@article{a7554dc4-cbed-4e2e-ba74-601b60e88319,
  abstract     = {Summary. The reasons that inhibitory factor VIII antibodies develop in only a fraction of patients with haemophilia A remain unclear, but studies of genetically related subjects have indicated that the immunological outcome of replacement therapy is to a large extent determined by patient-related risk factors. Non-genetic factors will also influence the inhibitor risk, since events challenging the immune system will elicit and stimulate immune regulatory processes with the potential of modifying the immune response. Further insight into the immunological pathways and risk factors involved will be important in order to better predict and prevent this complication. This review will briefly summarize the data obtained to date in unrelated and related subjects in the Malmö International Brother Study (MIBS) regarding genetic factors and discuss how these factors might interact with non-genetically determined factors and events.},
  author       = {Astermark, Jan},
  issn         = {1351-8216},
  language     = {eng},
  pages        = {66--70},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {Haemophilia},
  title        = {Inhibitor development: patient-determined risk factors.},
  url          = {http://dx.doi.org/10.1111/j.1365-2516.2008.01923.x},
  volume       = {16},
  year         = {2010},
}